The correct device in the pictures in Yle’s interesting article.
“A study, starting next autumn at HUS as a collaboration between the University of Helsinki and HUS, aims to identify subtypes of depression from brain images that predict the effectiveness of repetitive transcranial magnetic stimulation therapy.”
Here are Nexstim’s comments on LinkedIn;
Finding the right treatment for depression is often challenging and requires multiple trials.
A new study by the University of Helsinki and Helsinki University Hospital aims to improve treatment selection by analyzing brain imaging to identify depression subtypes that predict the efficacy of rTMS. By distinguishing patients who would benefit from this treatment, the study seeks to reduce ineffective treatments and accelerate recovery, allowing patients who are likely to benefit from rTMS to start treatment earlier.
This could lead to earlier, more targeted treatments, reduce costs, and improve patient outcomes.
Read the full article here: LinkedIn
Brainlab vie infoa perille; Linkedin
Rainer Birkenbach
Shaping the future of neurosurgery—together 
We were honored to welcome more than 40 attendees from across the US, representing hospitals nationwide, to this year’s Brainlab Neurosurgery Resident Program—an incredible few days of learning, connection, and innovation. With 9 distinguished expert speakers, we created an environment where hands-on learning, live demonstrations and thoughtful discussions took center stage.
One of the true highlights for me was speaking face-to-face with these talented young neurosurgeons. Hearing their perspectives and receiving direct feedback on how our technology fits into their clinical routines—and ultimately supports better outcomes for their patients—was incredibly valuable. 
At Brainlab, we believe that innovation thrives when diverse perspectives come together, including listening closely to the next generation of neurosurgeons. Young doctors bring fresh insight, curiosity, and an eagerness to challenge the status quo. We benefit greatly from these synergies and are proud to support their growth through educational programs like this.
Thank you to our expert faculty, the residents, and the Brainlab teams who brought this event to life. Your passion and engagement made this experience truly meaningful for all of us.
Together, we’re connecting minds and advancing care. 
#BrainlabResidentProgram #Surgery #Neurosurgery #Education
No major changes.
Kyösti probably has a cottage terrace project underway..
New research results on Alzheimer’s disease treatment published today.
Here are a few highlights:
24-week treatment slowed cognitive and functional decline compared to placebo
Significant improvements, e.g., in MMSE and ADAS-Cog tests
EEG measurements showed neurophysiological changes as a result of stimulation
TMS targeting was based on neuronavigation and consideration of individual brain structure
The study thus supports precisely the approach that Sinaptica is developing — and for which Nexstim is responsible for the hardware and software implementation. The SinaptiStim® system is based on Nexstim’s NBS 6 technology and EEG compatibility.
This collaboration has the potential to open up a completely new treatment area for Nexstim, where there are currently no commercially approved TMS solutions.
Sinaptica recently on LinkedIn;
Excited to share a positive peer-reviewed 52-week study published in Alzheimer’s Research & Therapy, showing that personalized #neuromodulation treatment slowed #Alzheimers in all three clinically measured areas: cognition, function, and behavior after one year.
This data builds on previous positive clinical studies and provides important additional evidence of long-term safety and treatment durability.
#neurotech #innovation #MedTech #AlzMoonshot #ENDALZ
See the full publication here: LinkedIn
The impact of the trade war on Nexstim is expected to be relatively minor. Nexstim already has a subsidiary in the United States, to which the devices sold there are delivered from Finland. In practice, the devices and supplies are sold from the Finnish company to Nexstim’s US subsidiary at zero margin, and customs duties are paid on this amount.
The sales margin last year was 79%, meaning that customs duties effectively apply to that 21 percent. With a simple multiplication, the impact of a 20% duty is calculated to be 4.2% of the final customer price in the United States.
Customs duties also burden competitors. Even if the devices were assembled in the United States, a large portion of the components would still come from abroad. Overall, it might even be more advantageous to acquire components in Finland with lower duties and send the finished devices from Finland to the United States, instead of ordering components from China (34% duties), Vietnam (46%), or other high-duty countries to the United States and handling assembly there.
Nexstim’s device has been involved in an epilepsy study.
Yeah, it’s probably just general panic here. Let’s see over the summer what the situation is in the fall. These kinds of dips have usually been pretty good buying opportunities.
An inquiry has been made in Hilma for a navigated TMS device.
Is this Phase 3, starting in 2025, already the one where Nexstim’s devices are intended to be used? No actual contract has been announced yet.
Sinaptica apparently announced a new investor yesterday:
This is how I’ve understood that the device delivered in March was the first for this 3rd phase. It will be tested until May. If there are improvements to be made, then possibly 1-2 more devices will be ordered in May. And then tested again. If this first one is satisfactory, then I suppose by early summer we’ll be ready to order the rest of the devices and kick off phase 3. I base this on an interview that Inderes published a few months ago.
If the worst-case scenario hits now and this mess causes a global recession, then it will certainly affect Nexstim too. On the other hand, one would think hospitals would still invest in these Nexstim devices, even if money is tight. We’ll see what kind of mess this creates 
StartUp Health recently on LinkedIn.
Very positive news from Sinaptica;
Exciting news in Alzheimer’s disease research!
Sinaptica Therapeutics, a clinical-stage company in the StartUp Health Alzheimer’s Moonshot community, leading the development of a new class of personalized neuromodulation therapies for Alzheimer’s disease and other primary neurodegenerative diseases, has announced that positive results from a 52-week Phase 2 study in patients with mild to moderate Alzheimer’s disease, conducted by the company’s scientific founder Dr. Giacomo Koch, were published in the peer-reviewed journal Alzheimer’s Research & Therapy.
The study met all primary and key secondary endpoints.
Key metrics such as CDR-SB, ADAS-Cog11, and ADCS-ADL showed a strong differentiation from placebo.
Disease progression was observed to slow significantly by 44%.
Patients maintained nearly all daily functions after 1 year compared to a significant decline in the placebo group.
The intervention was safe and well-tolerated, with very few minor adverse events reported.
Read more 
https://bwnews.pr/4cn5n61
Sorry… a bit repetitive
This is indeed relevant… Nexstim and Brainlab on the same stand; Linkedin… Nexstim
Exciting News: Brainlab and Nexstim at AANS 2025!
Join us at the American Association of Neurological Surgeons (AANS) Annual Meeting from April 25-27 at the Boston Convention and Exhibition Center. Visit us at Booth #818, Level 0, to explore our latest innovations in neurosurgery.
Brainlab and Nexstim combine forces to advance the neurosurgical experience! Now recognized as an essential technology in neurosurgery, Nexstim nTMS enables preoperative, non-invasive mapping of brain areas related to motor and language functions. Together with Elements for Cranial Planning, this powerful synergy supports surgeons in making informed decisions.
Visit our booth for a hands-on demonstration and see how this technology is shaping the future of neurosurgery.
Want to join? Click here: LinkedIn
Now it’s really going!
Sinaptica swept both awards at the Octane OC Neuro Tech Forum — the People’s Choice and Judge’s Choice — with industry experts weighing in and 84% selecting Sinaptica Therapeutics as the most promising innovation. CEO Ken Mariash accepted the awards. Reach out to learn more about our non-invasive #neuromodulation treatment for #Alzheimers.
#neurotech #innovation #MedTech #AlzMoonshot #ENDALZ #NTF2025
The device in the picture looks very much like a Nexstim device with Sinaptica stickers.